Alantos Joins DPP-4 Hunt With Help From France’s Servier
This article was originally published in The Pink Sheet Daily
Executive Summary
The Cambridge, Mass. company is touting its “second generation” dipeptidyl peptidase-4 inhibitor, headed for Phase II in the first quarter of 2007, as “a superior molecule to both Galvus and Januvia” for treatment of type 2 diabetes.
You may also be interested in...
Amgen’s Second Acquisition In Three Days Is Alantos
Amgen will gain entry into the diabetes market with a DPP-4 inhibitor in Phase IIa clinical development.
Amgen’s Second Acquisition In Three Days Is Alantos
Amgen will gain entry into the diabetes market with a DPP-4 inhibitor in Phase IIa clinical development.
Merck KGaA Builds On Diabetes Portfolio With DPP-IV Inhibitor
Merck signs licensing agreement for Phase II DPP-IV inhibitor with Glenmark.